Neratinib(Nerlynx)

This drug manufactured by Lucius Pharmaceuticals is a targeted therapy for HER2-positive breast cancer, with definite clinical efficacy, a standardized adverse reaction management plan, and favorable therapeutic cost-effectiveness.

Overview of Key Information for Neratinib.

Active Ingredient

The active ingredient is neratinib, with 40 mg per tablet.

Indicated Population

For adult patients with HER2-positive breast cancer.

Dosage and Administration

The recommended dosage is 240 mg (6 tablets) once daily, to be taken with meals. The specific treatment course shall be determined according to the patient’s condition.

Use in Special Populations

Dosage adjustment is required for patients with severe hepatic impairment. This drug is contraindicated in pregnant women and lactating women.

Overdosage

There is no specific antidote for overdosage. Symptomatic and supportive treatments should be administered.

Storage Conditions

Store the medicine at room temperature and protect it from moisture.

Pharmacokinetics

Pharmacokinetic data indicate that its half-life is approximately 14.6 hours, and it is mainly metabolized in the liver.

FDA，2021.06